Nemer Junior El Mouallem, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Virginia Commonwealth University School Of Medicine (Previously MCV) - Richmond VA
Rank: Assistant Professor
Years: 2018-Present

None Reported

Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials
Critical reviews in oncology/hematology
Volume: 93
Date: 11 2014
10.1016/j.critrevonc.2014.11.006

Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder
Clinical genitourinary cancer
Volume: 13
Date: 03 2015
10.1016/j.clgc.2015.02.010

Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration.
THe Journal of Urology
Volume: 196
Date: 12 2015
10.1016/j.juro.2015.12.082

BK Virus-associated urinary bladder cancer in a kidney transplant recipient: a case report and review of the pathogenesis
The American Journal of Hematology/Oncology
Volume: 13
Date: 03 2017
www.gotoper.com/publications/ajho/2017/2017mar/bk-virus-associated-urinar-bladder-cancer-in-a-kidney

Sarcomatoid renal cell carcinoma: Biology and treatment advances
Urologic Oncology
2018 Jun;36(6):265-271
Date: 06 2018
https://www.sciencedirect.com/science/article/abs/pii/S1078143917306257?via%3Dihub

Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor
Journal of Oncology Practice
2018 Aug;14(8):511-513. doi: 10.1200/JOP.18.00213.
Date: 08 2018
https://ascopubs.org/doi/10.1200/JOP.18.00213?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rf

Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies
Federal Practiticoner
2018 Aug; 35(Suppl 5): S62–S64.
Date: 08 2018
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248150/